Status:
COMPLETED
Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Bacterial Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
* To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection. * To determine the acquisition rate of ESBL produ...
Eligibility Criteria
Inclusion
- Patients admitted or transferred to the ICU/pulmonary/hematology units.
- Patients of either sex, 18 years of age or older
Exclusion
- Pregnant and nursing women. Female of childbearing potential without using any birth control methods. Female of childbearing potential using oral contraceptives during study period. (Note: penicillin and beta-lactamase inhibitors may prevent oral contraceptives from working properly, increasing the chance of pregnancy).
- Patients who have the contraindications of using Tazocin (pipercillin/tazobactam)
- Other exclusions apply.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
710 Patients enrolled
Trial Details
Trial ID
NCT00254696
Start Date
June 1 2004
End Date
March 1 2005
Last Update
April 15 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.